Investor Presentation Full Year 2021
23
Investor presentation
Full year 2021
Novo Nordisk has leading positions in diabetes, obesity and
haemophilia
Diabetes care
DKK
billion
800
600
400
Obesity care
DKK
billion
#1
50%
16
40%
12
30%
20%
200
10%
CAGR¹ value: 10.1%
0
Nov
2016
Haemophilia
DKK
billion
#1
80%
100
Novo NordiskⓇ
#3
50%
80
40%
60%
60
30%
40%
40
40
20%
20%
20
CAGR² value: 18.8%
CAGR³ value: 3.0%
10%
0%
0
0%
0
0%
Nov
2021
Nov
Market value
2019
Market value
Nov
2021
FY
FY
2016
NN value market share (RHS)
Global market position
NN value market share (RHS)
Global market position
Market value
NN value market share (RHS)
2020
Global market position
1 CAGR for 5-year period; 2 CAGR for 2-year period; 3 CAGR for 5-year period; Note: Annual sales figures for haemophilia A, B and bypassing agent segments, Recombinant and plasma derived products;
Source: Company reports for haemophilia market- FY21 numbers ready by Q1'22; IQVIA MAT, Nov 2021; Note: Diabetes and Obesity care market values are based on list prices in the US.
NN: Novo NordiskView entire presentation